Autologous Matrix-Induced Chondrogenesis, AMIC®, is an innovative biological surgical procedure developed by Geistlich Surgery for the treatment of traumatic chondral and osteochondral lesions. This unique single-step procedure combines the microfracturing method, which is an established first-line treatment, with the application of Chondro-Gide®, a porcine collagen bilayer matrix.
The functional principle of microfracturing is based on the release of multipotent mesenchymal progenitor cells, cytokines and growth factors from the subchondral bone. The super clot formed as a result of haemorrhage is covered and hence stabilised by the Chondro-Gide® matrix and fibrin glue.
Chondro-Gide® is a suitable scaffold that enhances the chondrogenic differentiation of mesenchymal stem cells and, in combination with fibrin glue, stimulates chondrocytes to enhance proteoglycan deposition.
AMIC® achieves pain relief and restores functionality in the joint with the goal to regain full mobility, allowing going back to previous lifestyle and activity level. It slows down cartilage degeneration with the intent to avoid or delay partial or total joint replacement surgery.